Eli Lilly Reports Foundayo Reduces Type 2 Diabetes Risk by 57%
Eli Lilly (LLY) announced that its oral obesity therapy, Foundayo at a dose of 17.2 mg, is associated with a 57% reduction in the risk of developing type 2 diabetes compared to placebo. This finding comes from additional analyses of the Phase 3 ATTAIN-1 trial. The results highlight the potential for Foundayo not only as an obesity treatment but also as a preventive measure against one of its major complications—type 2 diabetes. The announcement could bolster investor confidence in Lilly's pipeline and reinforce the drug’s value proposition, especially if it receives regulatory approval or is integrated into broader treatment guidelines. The market may view this news positively due to the growing global demand for effective obesity treatments with additional metabolic benefits.
Tickers: $LLY
Topics: clinical trial results obesity therapy type 2 diabetes prevention